-
PBMs not complying with federal probe: FTC
In June 2022, the Federal Trade Commission launched a probe into the business practices of pharmacy benefit managers and how they affect drug affordability and access. No PBM has fully complied with the probe, FTC Chair Lina Khan said in a recent letter obtained by Axios. -
A weight loss drug candidate could rival Ozempic
Viking Therapeutics reported Feb. 27 strong results from a phase 2 trial of a new drug that could rival other GLP-1 medications like Ozempic, Mounjaro and Wegovy. -
2 drugs nearing approval to know: Optum
UnitedHealth Group's Optum Rx is monitoring two drug candidates that might be approved in the next few months, according to its winter 2024 report. -
Mark Cuban's drug company to add another branded med
Mark Cuban Cost Plus Drug Co. will sell Euthyrox, its 21st brand-name drug, in March. -
For 1st time, state board sets a drug price ceiling
On Feb. 23, Colorado secured a national first by agreeing to establish a price ceiling on a medication, The Denver Post reported. -
FDA revokes approval of cancer drug Pepaxto
More than two and a half years after the FDA warned about an increased risk of death linked to Pepaxto, a multiple myeloma drug, the agency withdrew the medication's approval Feb. 23. -
New York asks FDA to address Singulair controversy
New York Attorney General Letitia James implored the FDA Feb. 22 to update Singulair's warning label after an uptick in pediatric mental health issues linked to the asthma and allergy drug. -
Moderna expects approval of 2nd RSV shot in 1st half of 2024
Pharmaceutical giant Moderna said it anticipates initial regulatory approvals of its respiratory syncytial virus vaccine will come in the first half of 2024, according to its Q4 earnings update published Feb. 22. -
AHA urges facilities to disconnect from Optum after cyberattacks
The American Hospital Association is urging healthcare facilities to disconnect from Optum systemes following a cyberattack on the insurer, The Wall Street Journal reported Feb. 22. -
State attorneys general call for federal PBM reforms
State attorneys general are urging Congress to pass three bills that would reform pharmacy benefit manager practices and bring more transparency to their work. -
Few options for patients who want to quit weight loss drugs
Research has shown patients often regain weight after halting use of popular weight loss drugs. But staying on medications like Ozempic and Wegovy indefinitely can be pricey. -
CVS partners with Grubhub
Grubhub has teamed up with CVS Pharmacy to deliver health and wellness products to consumers in 48 states. -
Nearly 4,000 weight loss drug prescriptions in 2023 were for US teens
There were around 4,000 prescriptions for weight loss drugs like Wegovy and Ozempic written for U.S. patients between the ages of 12 and 18 in 2023, alone, NBC News reported Feb. 21. -
Pharmacist explores delivering vaccines directly to white blood cells
Delivering vaccines directly into the body's immune cells could make the preventions even more effective, according to new research from a pharmaceutical scientist and professor at West Virginia University in Morgantown. -
AHA: Simplify hiring process for foreign pharmacists
As 2 in 5 hospitals report shortages of clinical pharmacists, the American Hospital Association on Feb. 20 urged the Labor Department to simplify the hiring process for immigrant pharmacists. -
AbbVie CEO to step down
Richard Gonzalez, the CEO of AbbVie since the drugmaker's inception in 2013, is exiting the role on July 1. -
What's old is new again in the fight against cancer
Drugmakers are pouring billions of dollars toward the advancement of treatments that target cancer more precisely than mainstay treatments like radiation and chemotherapy. -
10 drugs now in shortage
As clinicians ration penicillin and two more cancer injectable drugs fell into shortage, supply strained recently for nearly a dozen other medications. -
Buzz for gene therapies is loud, but drugmakers struggle to get treatments off the ground
Roctavian held promise of treating hemophilia A, but has only been used for one patient since its approval in June 2023, Bloomberg reported Feb. 20. -
FDA places clinical holds on 2 drug studies
RAPT Therapeutics, a San Francisco-based pharmaceutical company, said Feb. 20 that two of its clinical trials are on pause because of one patient's liver failure.
Page 22 of 50